Cargando…

Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles

Combinatorial drug delivery is a way of advanced cancer treatment that at present represents a challenge for researchers. Here, we report the efficient entrapment of two clinically used single-agent drugs, doxorubicin and sorafenib, against hepatocellular carcinoma. Biocompatible and biodegradable p...

Descripción completa

Detalles Bibliográficos
Autores principales: Babos, György, Biró, Emese, Meiczinger, Mónika, Feczkó, Tivadar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403728/
https://www.ncbi.nlm.nih.gov/pubmed/30960820
http://dx.doi.org/10.3390/polym10080895
_version_ 1783400686249050112
author Babos, György
Biró, Emese
Meiczinger, Mónika
Feczkó, Tivadar
author_facet Babos, György
Biró, Emese
Meiczinger, Mónika
Feczkó, Tivadar
author_sort Babos, György
collection PubMed
description Combinatorial drug delivery is a way of advanced cancer treatment that at present represents a challenge for researchers. Here, we report the efficient entrapment of two clinically used single-agent drugs, doxorubicin and sorafenib, against hepatocellular carcinoma. Biocompatible and biodegradable polymeric nanoparticles provide a promising approach for controlled drug release. In this study, doxorubicin and sorafenib with completely different chemical characteristics were simultaneously entrapped by the same polymeric carrier, namely poly(d,l-lactide-co-glycolide) (PLGA) and polyethylene glycol-poly(d,l-lactide-co-glycolide) (PEG-PLGA), respectively, using the double emulsion solvent evaporation method. The typical mean diameters of the nanopharmaceuticals were 142 and 177 nm, respectively. The PLGA and PEG-PLGA polymers encapsulated doxorubicin with efficiencies of 52% and 69%, respectively, while these values for sorafenib were 55% and 88%, respectively. Sustained drug delivery under biorelevant conditions was found for doxorubicin, while sorafenib was released quickly from the PLGA-doxorubicin-sorafenib and PEG-PLGA-doxorubicin-sorafenib nanotherapeutics.
format Online
Article
Text
id pubmed-6403728
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64037282019-04-02 Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles Babos, György Biró, Emese Meiczinger, Mónika Feczkó, Tivadar Polymers (Basel) Article Combinatorial drug delivery is a way of advanced cancer treatment that at present represents a challenge for researchers. Here, we report the efficient entrapment of two clinically used single-agent drugs, doxorubicin and sorafenib, against hepatocellular carcinoma. Biocompatible and biodegradable polymeric nanoparticles provide a promising approach for controlled drug release. In this study, doxorubicin and sorafenib with completely different chemical characteristics were simultaneously entrapped by the same polymeric carrier, namely poly(d,l-lactide-co-glycolide) (PLGA) and polyethylene glycol-poly(d,l-lactide-co-glycolide) (PEG-PLGA), respectively, using the double emulsion solvent evaporation method. The typical mean diameters of the nanopharmaceuticals were 142 and 177 nm, respectively. The PLGA and PEG-PLGA polymers encapsulated doxorubicin with efficiencies of 52% and 69%, respectively, while these values for sorafenib were 55% and 88%, respectively. Sustained drug delivery under biorelevant conditions was found for doxorubicin, while sorafenib was released quickly from the PLGA-doxorubicin-sorafenib and PEG-PLGA-doxorubicin-sorafenib nanotherapeutics. MDPI 2018-08-09 /pmc/articles/PMC6403728/ /pubmed/30960820 http://dx.doi.org/10.3390/polym10080895 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Babos, György
Biró, Emese
Meiczinger, Mónika
Feczkó, Tivadar
Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
title Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
title_full Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
title_fullStr Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
title_full_unstemmed Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
title_short Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
title_sort dual drug delivery of sorafenib and doxorubicin from plga and peg-plga polymeric nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403728/
https://www.ncbi.nlm.nih.gov/pubmed/30960820
http://dx.doi.org/10.3390/polym10080895
work_keys_str_mv AT babosgyorgy dualdrugdeliveryofsorafenibanddoxorubicinfromplgaandpegplgapolymericnanoparticles
AT biroemese dualdrugdeliveryofsorafenibanddoxorubicinfromplgaandpegplgapolymericnanoparticles
AT meiczingermonika dualdrugdeliveryofsorafenibanddoxorubicinfromplgaandpegplgapolymericnanoparticles
AT feczkotivadar dualdrugdeliveryofsorafenibanddoxorubicinfromplgaandpegplgapolymericnanoparticles